List of works - Jonas Lategahn

A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives

scientific article published in Scientific Reports

An Unusual Intramolecular Halogen Bond guides Conformational Selection.

scientific article

Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA

scientific article published in 2024

C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?

scientific article published on 23 July 2018

Characterization of Covalent Pyrazolopyrimidine-MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7)

scientific article published on 31 May 2019

Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer

scientific article published on 18 December 2015

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor

scientific article published on 22 February 2017

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S

scientific article published on 04 October 2019

Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR

scientific article

Insights into the Kinetics of the Resistance Formation of Bacteria against Ciprofloxacin Poly(2-methyl-2-oxazoline) Conjugates

scientific article published on 11 July 2018

Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer.

scientific article published on 27 November 2017

Metal-free direct oxidative intermolecular diarylation of anilides at ambient temperature assisted by cascade selective formation of C–C and C–N bonds

scientific article published on 13 February 2012

Organocatalytic, Oxidative, Intramolecular CH Bond Amination and Metal-free Cross-Amination of Unactivated Arenes at Ambient Temperature

scientific article published on 26 July 2011

Overcoming EGFR-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

scientific article published in Nature Communications

RASPELD to Perform High-End Screening in an Academic Environment toward the Development of Cancer Therapeutics

article

Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain

scientific article published on 24 September 2020

Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases

scientific article published on 28 August 2019

Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.

scientific article

Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach

scientific article

Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.

scientific article published on 21 February 2019

Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.

scientific article

List of works by Jonas Lategahn

A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives

An Unusual Intramolecular Halogen Bond guides Conformational Selection.

Avapritinib-based SAR studies unveil a binding pocket in KIT and PDGFRA

C797S Resistance: The Undruggable EGFR Mutation in Non-Small Cell Lung Cancer?

Characterization of Covalent Pyrazolopyrimidine-MKK7 Complexes and a Report on a Unique DFG-in/Leu-in Conformation of Mitogen-Activated Protein Kinase Kinase 7 (MKK7)

Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer

Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S

Insight into the Inhibition of Drug-Resistant Mutants of the Receptor Tyrosine Kinase EGFR

Insights into the Kinetics of the Resistance Formation of Bacteria against Ciprofloxacin Poly(2-methyl-2-oxazoline) Conjugates

Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer.

Metal-free direct oxidative intermolecular diarylation of anilides at ambient temperature assisted by cascade selective formation of C–C and C–N bonds

Organocatalytic, Oxidative, Intramolecular CH Bond Amination and Metal-free Cross-Amination of Unactivated Arenes at Ambient Temperature

Overcoming EGFR-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors

RASPELD to Perform High-End Screening in an Academic Environment toward the Development of Cancer Therapeutics

Resistance to avapritinib in PDGFRA-driven GIST is caused by secondary mutations in the PDGFRA kinase domain

Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases

Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.

Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach

Targeting the MKK7-JNK (Mitogen-Activated Protein Kinase Kinase 7-c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors.

Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.